$CODE / $BKLLF ~ Developing a transdermal or oral mucosal delivery of these drugs should lead to the lessening of the dosage required and the common side effects felt by current users of these drugs for their on-label treatment for lupus, rheumatoid arthritis and malaria.
https://finance.yahoo.com/news/codebase-ventu...00814.html